ATE476512T1 - Zuckertransferase gnt-v mit angiogener wirkung - Google Patents

Zuckertransferase gnt-v mit angiogener wirkung

Info

Publication number
ATE476512T1
ATE476512T1 AT02792072T AT02792072T ATE476512T1 AT E476512 T1 ATE476512 T1 AT E476512T1 AT 02792072 T AT02792072 T AT 02792072T AT 02792072 T AT02792072 T AT 02792072T AT E476512 T1 ATE476512 T1 AT E476512T1
Authority
AT
Austria
Prior art keywords
angiogenic effect
protein
neovascularization
sugar transferase
gnt
Prior art date
Application number
AT02792072T
Other languages
English (en)
Inventor
Naoyuki Taniguchi
Eiji Miyoshi
Takashi Saito
Original Assignee
Suntory Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Holdings Ltd filed Critical Suntory Holdings Ltd
Application granted granted Critical
Publication of ATE476512T1 publication Critical patent/ATE476512T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/0115—N-Acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase (2.4.1.150)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
AT02792072T 2002-01-09 2002-12-27 Zuckertransferase gnt-v mit angiogener wirkung ATE476512T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002002056 2002-01-09
PCT/JP2002/013879 WO2003060131A1 (en) 2002-01-09 2002-12-27 SUGAR TRANSFERASE GnT-V HAVING ANGIOGENIC EFFECT

Publications (1)

Publication Number Publication Date
ATE476512T1 true ATE476512T1 (de) 2010-08-15

Family

ID=19190703

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02792072T ATE476512T1 (de) 2002-01-09 2002-12-27 Zuckertransferase gnt-v mit angiogener wirkung

Country Status (8)

Country Link
US (1) US7662769B2 (de)
EP (1) EP1460134B1 (de)
JP (1) JP4371819B2 (de)
AT (1) ATE476512T1 (de)
AU (1) AU2002362185A1 (de)
CA (1) CA2472381C (de)
DE (1) DE60237232D1 (de)
WO (1) WO2003060131A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003091402A2 (en) 2002-04-23 2003-11-06 University Of Georgia Research Foundation, Inc. N-ACETYLGLUCOSAMINYLTRANSFERASE Vb CODING SEQUENCE, RECOMBINANT CELLS AND METHODS
RU2672564C2 (ru) * 2014-09-09 2018-11-16 Эррера Артуро Солис Способы лечения и предотвращения заболеваний глаз, расстройств и патологических состояний меланином и аналогами, предшественниками и производными меланина

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3979678B2 (ja) 1992-08-24 2007-09-19 サントリー株式会社 新規糖転移酵素及びそれをコードする遺伝子並びに該酵素の製造方法
JPH0984582A (ja) * 1995-09-21 1997-03-31 Kirin Brewery Co Ltd 糖転移酵素活性を強化した動物細胞、糖鎖改変糖蛋白質ならびにその製造方法
EP0867450B1 (de) * 1995-10-24 2004-08-11 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute TFPI-verwandte Peptide die das Wachstums von glatten Muskelzellen inhibieren
JPH10137000A (ja) 1996-11-01 1998-05-26 Suntory Ltd 癌転移抑制物質のスクリーニング方法
FR2799465B1 (fr) 1999-10-12 2004-02-13 Centre Nat Rech Scient Peptides ayant une activite de stimulation de la reponse immunitaire et de regeneration tissulaire
GB0026134D0 (en) 2000-10-25 2000-12-13 Eurogene Ltd Peptides and their use

Also Published As

Publication number Publication date
AU2002362185A1 (en) 2003-07-30
WO2003060131A1 (en) 2003-07-24
CA2472381C (en) 2014-04-29
DE60237232D1 (de) 2010-09-16
EP1460134A4 (de) 2005-11-09
JP4371819B2 (ja) 2009-11-25
JPWO2003060131A1 (ja) 2005-05-19
US20050148516A1 (en) 2005-07-07
CA2472381A1 (en) 2003-07-24
US7662769B2 (en) 2010-02-16
EP1460134B1 (de) 2010-08-04
EP1460134A1 (de) 2004-09-22

Similar Documents

Publication Publication Date Title
ATE333888T1 (de) Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
WO2001085664A3 (en) Compounds and methods for regulating bacterial growth and pathogenesis
MY122189A (en) Farnesyl protein transferase inhibitors for treating arthropathies
BR0315157A (pt) Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
BR0115482A (pt) Composição de sacralose melhorada e processo para sua preparação
DE69739035D1 (de) Zusammensetzungen und Methoden zur Behandlung von Infektionen unter Verwendung von Indolicidinanalogen
ATE392430T1 (de) Verfahren zur herstellung von dipeptiden
SE0102948L (sv) Implantat och fastdragnings- och distansorgan för sådant implantat
ATE447858T1 (de) Pharmazeutische zusammensetzung für muskelanabolismus
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
ES2180948T3 (es) Peptido que proviene de una forma soluble de la acetilcolinesterasa, activo como modulador del canal.
BR0315864A (pt) Composições e processos para a modificação efeitos tóxicos de compostos proteináceos
AU2002345804A1 (en) Antimicrobially active peptide
ATE211719T1 (de) Korrosionsinhibitoren enthaltender injektionszement
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall
DE60237232D1 (de) ZUCKERTRANSFERASE GnT-V MIT ANGIOGENER WIRKUNG
DK1392126T3 (da) Fremgangsmåde til forbedring af et proteinprodukt
DE60329115D1 (de) Tumorantigenprotein und dessen verwendung
DK1117682T3 (da) Chi-conotoksin-peptider som inhibitorer af neuronale amintransportere
DE60236330D1 (de) Biologisch aktive Peptide
DK0655244T3 (da) Sammensætning på basis af aminosyrer til behandling af infektioner
SG48485A1 (en) Stabilization of non-halogenated 3-isothiazolones in aggressive systems
ATE382262T1 (de) Fungizide zusammensetzung auf der basis von saurem kaliumphosphit
WO2003059387A3 (en) Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis
AR024483A1 (es) Proteinas insecticidas y nematocidas

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties